Attached files
file | filename |
---|---|
EX-32.1 - EX-32.1 - Aimmune Therapeutics, Inc. | aimt-ex321_19.htm |
EX-31.2 - EX-31.2 - Aimmune Therapeutics, Inc. | aimt-ex312_8.htm |
EX-31.1 - EX-31.1 - Aimmune Therapeutics, Inc. | aimt-ex311_6.htm |
EX-23.1 - EX-23.1 - Aimmune Therapeutics, Inc. | aimt-ex231_18.htm |
EX-21.1 - EX-21.1 - Aimmune Therapeutics, Inc. | aimt-ex211_13.htm |
EX-10.8 - EX-10.8 - Aimmune Therapeutics, Inc. | aimt-ex108_347.htm |
EX-10.2D - EX-10.2D - Aimmune Therapeutics, Inc. | aimt-ex102d_111.htm |
EX-4.7 - EX-4.7 - Aimmune Therapeutics, Inc. | aimt-ex47_705.htm |
10-K - 10-K - Aimmune Therapeutics, Inc. | aimt-10k_20191231.htm |
Exhibit 32.2
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Annual Report of Aimmune Therapeutics, Inc. (the “Company”) on Form 10-K for the period ending December 31, 2019 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:
|
(1) |
The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and |
|
(2) |
The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company. |
Date: February 27, 2020 |
|
By: |
/s/ Eric H. Bjerkholt |
|
|
|
Eric H. Bjerkholt Chief Financial Officer |
|
|
|
(Principal Financial and Accounting Officer) |